Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The funding will accelerate Sinopia’s data-driven drug discovery efforts
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Harbour BioMed brings advanced antibody discovery platforms to the table
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Subscribe To Our Newsletter & Stay Updated